Healios KK (JP:4593) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Healios KK has made progress in its application for conditional approval of its MultiStem product for treating Acute Respiratory Distress Syndrome (ARDS) in Japan. Following positive results in Phase 2 studies, the company has reached an agreement with regulatory authorities on manufacturing details and is preparing for commercial production. Plans are underway for further consultation on the clinical aspects of the application in January.
For further insights into JP:4593 stock, check out TipRanks’ Stock Analysis page.